Journal
JOURNAL OF SURGICAL RESEARCH
Volume 147, Issue 2, Pages 247-252Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.jss.2008.02.048
Keywords
cancer; polymeric drug carrier; lymphatic transport; cancer chemotherapy
Categories
Funding
- NCI NIH HHS [R21 CA132033-01, L30 CA136330-02, R21 CA132033, L30 CA136330] Funding Source: Medline
- NCRR NIH HHS [P20 RR0155563, P20 RR015563, P20 RR015563-086738] Funding Source: Medline
Ask authors/readers for more resources
Background. Breast cancers typically spread to regional lymph nodes once they disseminate from the primary tumor, thus adequate evaluation and treatment of the axillary lymph nodes is paramount in early stage disease. One significant problem with current therapy is the side effects chemotherapy agents create systemically, either alone or in combination. The purpose of this study is to determine whether lymphatically targeted cisplatin carriers will increase the localized dose in lymphatic metastases without systemic toxicities. Methods. Hyaluronan (HA) is a highly biocompatible polymer that follows lymphatic drainage from the interstitial spaces. We formed complexes of HA and cisplatin by non-covalent conjugation. Complexes were injected subcutaneously into the upper mammary fat pad of female rats, and the tissue distribution determined. Results. Cisplatin-HA contained up to 0.25 w/w of Pt and released drug with a half-life of 10 h in saline. Cisplatin-HA conjugates had high anti-tumor activity in vitro similar to the free drug: cisplatin-HA IC50 7 mu g/mL in MCF7 and MDA-MB-231 human breast cancer cells (free cisplatin IC50 7 mu g/mL). Cisplatin-HA conjugates were well tolerated in rodents with no signs of injection site morbidity or major organ toxicity after 96 h. The area-under-the-curve of cisplatin in the axially lymph nodes after injection with cisplatin-RA increased 74% compared with normal cisplatin. Conclusions. This study demonstrates a novel intra-lymphatic drug delivery method in breast cancer to preferentially treat at-risk regional lymph nodes and avoid systemic toxicities. Further in vivo testing related to efficacy of this approach with regard to survival, toxicity, and pharmacokinetics is warranted to support its use in human trials. (C) 2008 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available